{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:35:24Z","timestamp":1768397724692,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.clinthera.2006.05.012","type":"journal-article","created":{"date-parts":[[2006,7,25]],"date-time":"2006-07-25T11:57:04Z","timestamp":1153828624000},"page":"679-688","source":"Crossref","is-referenced-by-count":50,"title":["Effects of 1 Year of Treatment with Pioglitazone or Rosiglitazone Added to Glimepiride on Lipoprotein (a) and Homocysteine Concentrations in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Multicenter, Randomized, Double-Blind, Controlled Clinical Trial"],"prefix":"10.1016","volume":"28","author":[{"given":"Giuseppe","family":"Derosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arrigo F.G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gaddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardina","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario N.","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibilla A.T.","family":"Salvadeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Pricolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro D.","family":"Ragonesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.05.012_bib1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1517\/13543784.12.7.1179","article-title":"Thiazolidinediones-some recent developments","volume":"12","author":"Stumvoll","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2006.05.012_bib2","first-page":"406","article-title":"Thiazolidinediones in diabetes: Current status and future outlook","volume":"4","author":"Camp","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2006.05.012_bib3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/diabetes.52.6.1364","article-title":"Pioglitazone reduces hepaticfat content and augments splanchnic glucose uptake in patients with type 2 diabetes","volume":"52","author":"Bajaj","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2006.05.012_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1050-1738(02)00187-1","article-title":"Addressing the insulin resistance syndrome: A role for the thiazolidinediones","volume":"12","author":"Zimmet","year":"2002","journal-title":"Trends Cardiomsc Med"},{"key":"10.1016\/j.clinthera.2006.05.012_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14740338.2.6.581","article-title":"Hepatotoxicity of thiazolidinediones","volume":"2","author":"Isley","year":"2003","journal-title":"Expert Opin DrugSaf"},{"key":"10.1016\/j.clinthera.2006.05.012_bib6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2165\/00003495-200363130-00004","article-title":"Thiazolidinediones in type 2 diabetes mellitus: Current clinical evidence","volume":"63","author":"Diamant","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2006.05.012_bib7","first-page":"511","article-title":"Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)","volume":"63","author":"Dubois","year":"2002","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.clinthera.2006.05.012_bib8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0149-2918(04)90074-4","article-title":"Metabolic effects of pioglitazone and rosightazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelvemonth, multicenter, double-blind, randomized, controlled, parallel-group trial","volume":"26","author":"Derosa","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.05.012_bib9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0149-2918(03)80068-1","article-title":"A randomized, doubleblind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus","volume":"25","author":"Herz","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.05.012_bib10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1185\/030079902125001236","article-title":"An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes","volume":"18","author":"Vongthavaravat","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2006.05.012_bib11","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.2337\/diacare.25.11.2058","article-title":"A comparison of the effects of rosightazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes","volume":"25","author":"St John Sutton","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.05.012_bib12","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1210\/jc.2002-021786","article-title":"Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes","volume":"88","author":"Pavo","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.05.012_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1291\/hypres.28.917","article-title":"Thiazolidinedione effects on blood pressure in diabetic patients with meta bolic syndrome treated with glimepiride","volume":"28","author":"Derosa","year":"2005","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2006.05.012_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.diabres.2004.10.007","article-title":"A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome","volume":"69","author":"Derosa","year":"2005","journal-title":"Diabetes Res Clin Proct"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.05.012_bib15","first-page":"S21","article-title":"Screening for diabetes","volume":"24","author":"American Diabetes Association","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.05.012_bib16","series-title":"Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity","year":"1997"},{"key":"10.1016\/j.clinthera.2006.05.012_bib17","first-page":"151","article-title":"1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee","volume":"17","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2006.05.012_bib18","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.05.012_bib19","first-page":"S44","article-title":"Nutrition recommendations and principles for people with diabetes mellitus (Position Statement)","volume":"24","author":"American Diabetes Association","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.05.012_bib20","series-title":"International Ethical Guidelines for Biomedical Research Involving Human Subjects","year":"2002"},{"key":"10.1016\/j.clinthera.2006.05.012_bib21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: Insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2006.05.012_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1126\/science.635569","article-title":"The glycosylation of hemoglobin: Relevance to diabetes mellitus","volume":"200","author":"Bunn","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2006.05.012_bib23","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1464-5491.1999.00166.x","article-title":"A desktop guide to type 2 diabetes mellitus","volume":"16","year":"1999","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2006.05.012_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF01225569","article-title":"Determination of total serum insulin (IRI) in insulin-treated diabetic patients","volume":"8","author":"Heding","year":"1972","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2006.05.012_bib25","first-page":"121","article-title":"Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA II)","volume":"15","author":"Borner","year":"1977","journal-title":"J Clin Chem Clin Biochem"},{"key":"10.1016\/j.clinthera.2006.05.012_bib26","series-title":"Methods of Enzymatic Analysis","first-page":"1831","article-title":"Triglycerides determination afterenzymatic hydrolysis","author":"Wahlefeld","year":"1974"},{"key":"10.1016\/j.clinthera.2006.05.012_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI103182","article-title":"The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum","volume":"34","author":"Havel","year":"1955","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2006.05.012_bib28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2006.05.012_bib29","first-page":"249","article-title":"Lipoprotein(a): Structure, biology, and clinical relevance","volume":"36","author":"Scanu","year":"1991","journal-title":"Adv Intern Med"},{"key":"10.1016\/j.clinthera.2006.05.012_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0014-5793(83)80182-3","article-title":"Protein composition of Lp(a) lipoprotein from human plasma","volume":"154","author":"Utermann","year":"1983","journal-title":"FEBS Lett"},{"key":"10.1016\/j.clinthera.2006.05.012_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0378-4347(87)80438-3","article-title":"Determination of free and total homocysteine in human plasma by high-performance chromatography with fluorescence detection","volume":"422","author":"Araki","year":"1987","journal-title":"J Chromatogr"},{"key":"10.1016\/j.clinthera.2006.05.012_bib32","series-title":"Statistical Principles in Experimental Design","author":"Winer","year":"1971"},{"key":"10.1016\/j.clinthera.2006.05.012_bib33","doi-asserted-by":"crossref","first-page":"57U","DOI":"10.1016\/S0002-9149(98)00954-0","article-title":"Lipoprotein(a) as a risk factor for coronary artery disease","volume":"82","author":"Marcovina","year":"1998","journal-title":"Am J Cordial"},{"key":"10.1016\/j.clinthera.2006.05.012_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2796.2002.00997.x","article-title":"Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden","volume":"252","author":"Glader","year":"2002","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2006.05.012_bib35","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1378\/chest.121.5.1589","article-title":"Elevated serum lipoprotein(a) level is an independent marker of severity of thoracic aortic atherosclerosis","volume":"121","author":"Peltier","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2006.05.012_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1054\/jocn.2001.1030","article-title":"Relation of lipid and lipoprotein(a) to ischaemic stroke","volume":"9","author":"Misirli","year":"2002","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.clinthera.2006.05.012_bib37","first-page":"56","article-title":"The atherogenic lipid profile is associated with type 2 diabetes and some of its treatment modalities","volume":"16","author":"Lin","year":"2003","journal-title":"Diabetes Nutr Metab"},{"key":"10.1016\/j.clinthera.2006.05.012_bib38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1464-5491.2002.00645.x","article-title":"Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in type 2 diabetic patients","volume":"19","author":"Maca","year":"2002","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2006.05.012_bib39","first-page":"127","article-title":"Lipoprotein(a) concentrations in patients with type 2 diabetes mellitus without cardiovascular disease: Relationship to metabolic parameters and diabetic complications","volume":"12","author":"Tarkun","year":"2002","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2006.05.012_bib40","first-page":"471","article-title":"Hyperhomo-cysteinemia: A new risk factor for degenerative diseases","volume":"48","author":"Herrmann","year":"2002","journal-title":"Clin Lab"},{"key":"10.1016\/j.clinthera.2006.05.012_bib41","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/ajcn\/76.6.1279","article-title":"Homocysteine, cardiovascular disease riskfactors, and habitual diet in the French Supplementation with Antioxidant Vitamins and Minerals Study","volume":"76","author":"Mennen","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clinthera.2006.05.012_bib42","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2174\/0929867033456864","article-title":"Folate and homocysteine metabolism: Therapeutic targets in cardiovascular and neurodegenerative disorders","volume":"10","author":"Mattson","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clinthera.2006.05.012_bib43","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0002-9149(03)00281-9","article-title":"Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries","volume":"91","author":"Schnyder","year":"2003","journal-title":"Am J Cordial"},{"key":"10.1016\/j.clinthera.2006.05.012_bib44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0149-2918(02)85040-8","article-title":"Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records","volume":"24","author":"Boyle","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.05.012_bib45","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0149-2918(03)80109-1","article-title":"Glimepiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience","volume":"25","author":"Massi-Benedetti","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.05.012_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/713782132","article-title":"Glitazones: Clinical effects and molecular mechanisms","volume":"34","author":"Stumvoll","year":"2002","journal-title":"Ann Med"},{"key":"10.1016\/j.clinthera.2006.05.012_bib47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1185\/030079902125001038","article-title":"Differences in lipid profiles of patients given rosightazone followed by pioglitazone","volume":"18","author":"LaCivita","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2006.05.012_bib48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0026-0495(03)00033-7","article-title":"The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus","volume":"52","author":"Ko","year":"2003","journal-title":"Metabolism"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T12:27:59Z","timestamp":1587126479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806001238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0149291806001238"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.05.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}